Cargando…
Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study,...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/ https://www.ncbi.nlm.nih.gov/pubmed/36551858 http://dx.doi.org/10.3390/biomedicines10123102 |
_version_ | 1784855701529559040 |
---|---|
author | Zellmer, Johannes Yen, Hsi-Yu Kaiser, Lena Gildehaus, Franz Josef Böning, Guido Steiger, Katja Hacker, Marcus Bartenstein, Peter Todica, Andrei Haug, Alexander R. Ilhan, Harun |
author_facet | Zellmer, Johannes Yen, Hsi-Yu Kaiser, Lena Gildehaus, Franz Josef Böning, Guido Steiger, Katja Hacker, Marcus Bartenstein, Peter Todica, Andrei Haug, Alexander R. Ilhan, Harun |
author_sort | Zellmer, Johannes |
collection | PubMed |
description | Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus. |
format | Online Article Text |
id | pubmed-9775670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97756702022-12-23 Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors Zellmer, Johannes Yen, Hsi-Yu Kaiser, Lena Gildehaus, Franz Josef Böning, Guido Steiger, Katja Hacker, Marcus Bartenstein, Peter Todica, Andrei Haug, Alexander R. Ilhan, Harun Biomedicines Article Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study, we investigated the synergistic and potentially enhanced efficacy of a combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model. Baseline [68Ga]Ga-DOTA-TATE PET scans were obtained five days after athymic CD1 mice were inoculated with AR42J tumor cells, before separating the animals into four groups. Group 1 received a placebo, group 2 everolimus, group 3 a placebo and PRRT, and group 4 everolimus and PRRT. The treatment response was monitored by manually measuring the tumor volumes (manual tumor volume, MTV) and conducting sequential [68Ga]Ga-DOTA-TATE PET scans at one, two, and four weeks after treatment induction. The biological tumor volume (BTV) was derived from PET scans using threshold-based volume of interest (VOI) measurements. Tracer uptake was measured semi-quantitatively as a tumor to background ratio (TBR). Mice were euthanized due to excessive tumor growth according to the ethics protocol; blood samples were drawn for the preparation of full blood counts and kidneys were obtained for histological analysis. For the histological assessment, a standardized score (renal damage score, RDS) was used. Full blood counts showed significantly increased numbers of neutrophils and lymphocytes in the groups receiving PRRT. All other parameters did not differ relevantly. In the histological analysis, groups receiving PRRT had a significantly higher RDS, whereas everolimus only tended to cause an increase in the RDS. Mice in groups 1 and 2 had to be euthanized due to excessive tumor growth two weeks after the start of the therapy, whereas follow-up in groups 3 and 4 comprised four weeks. PRRT significantly inhibited tumor growth; the administration of everolimus did not induce an additional effect. A good correlation existed between MTV and BTV. PRRT significantly reduced the TBR. [68Ga]Ga-DOTA-TATE PET is suitable for monitoring tumor growth in the applied model. The high efficacy of [177Lu]Lu-DOTA-TATE is not enhanced by the combination with everolimus. MDPI 2022-12-01 /pmc/articles/PMC9775670/ /pubmed/36551858 http://dx.doi.org/10.3390/biomedicines10123102 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zellmer, Johannes Yen, Hsi-Yu Kaiser, Lena Gildehaus, Franz Josef Böning, Guido Steiger, Katja Hacker, Marcus Bartenstein, Peter Todica, Andrei Haug, Alexander R. Ilhan, Harun Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title | Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title_full | Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title_fullStr | Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title_full_unstemmed | Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title_short | Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors |
title_sort | evaluation of the efficacy of a combined treatment using the mtor-inhibitor everolimus and [177lu]lu-dota-tate in nude cd1 mice with sstr-expressing pancreatic ar42j xenograft tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/ https://www.ncbi.nlm.nih.gov/pubmed/36551858 http://dx.doi.org/10.3390/biomedicines10123102 |
work_keys_str_mv | AT zellmerjohannes evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT yenhsiyu evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT kaiserlena evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT gildehausfranzjosef evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT boningguido evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT steigerkatja evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT hackermarcus evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT bartensteinpeter evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT todicaandrei evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT haugalexanderr evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors AT ilhanharun evaluationoftheefficacyofacombinedtreatmentusingthemtorinhibitoreverolimusand177luludotatateinnudecd1micewithsstrexpressingpancreaticar42jxenografttumors |